Zai Lab (ZLAB) Q2 FY26 earnings call

Zai Lab is transforming into a global biopharmaceutical company, marked by significant pipeline advancements, including its first U.S. regulatory submission expected next year and a U.S. product launch anticipated in 2028. The company reported a commercially profitable quarter with sequential revenue growth, while strategically investing in its innovative global pipeline. Management is focused on disciplined capital allocation and expects operating expenses to remain stable through the remainder of the year.